Kornimate/medical-research-clean huggingface dataset:
care of the dry skin with physiogel ai lotion® (w0156)

Conditions: Eczema

Summary: dry skin is a physiological condition and is characterized in contrast to greasy skin by roughness, desquamation and lack of brightness of the skin surface. subjectively, feelings of tension, burning and itching can occur. dry skin needs special care due to its structural and functional characteristics.we monitor an application test the dermatocosmetics oilatum physiogel ai lotion and physiogel lotion. this is to be accomplished with patients having dry skin. the influence on the roughness of skin, desquamation, feeling of tingle, burning and itching should be documented. if sleep quality is disturbed by tingle or itch, this will be monitored, too.

the included patients use the lotion twice daily for a two-week period. if not sufficient it can be continued up to a four-weeks period. additionally, the patient receives a documentation sheets to note several parameters. in a sensory assessment, product specific parameter such as spreadability, permeability, lubricating, smell of lotion and cosmetic acceptance during the treatment will be assessed (at the beginning, after 2 weeks, after 4 weeks, 2 weeks after stopping treatment). after four weeks the skin care measurement will be terminated and the patient can continue with a treatment of his choice. a monitoring of at least 50 patients per preparation is intended.

Eligibility criteria:
inclusion criteria: 1. patients age: over 18 years 2. willing to apply skin care for 2 to 4 weeks, twice daily 3. willing to fulfill questionnaires / home diaries: self-perception of roughness of the skin, desquamation of the skin, lack of skin brightness, feelings of tension and itching exclusion criteria: 1. participation in any other research study during the previous 4 weeks. 2. previous participation in this study. 3. concurrent participation in any other research study involving an investigational product. 4. current need for the use of topical steroids. 5. history of skin disease or allergy likely to interfere with the study or known sensitivity to the test product or its ingredients. 6. subjects considered unable or unlikely to fulfill diaries. 7. employees of (cro) or stiefel laboratories, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee. 8. history of cancer. 9. recent immunization (less than 10 days prior to the use of the test product).

Keywords: dry skin
efs of the cardiomech mvrs

Conditions: Mitral Regurgitation

Summary: safety and performance evaluation of the cardiomech mitral valve repair system (mvrs) in patients with degenerative mitral valve regurgitation.

the purpose of the clinical study is to obtain clinical data on the cardiomech mitral valve repair system (mvrs) in patients diagnosed with moderate to severe (≥3+) or severe (≥4+), symptomatic, degenerative mitral regurgitation and who are determined to be at intermediate or high surgical risk for mitral valve repair, as assessed by the site's multidisciplinary heart team.

Eligibility criteria:
inclusion criteria: * eighteen (18) years of age or greater * moderate to severe (≥3+) or severe (≥4+) mitral valve regurgitation (per american society of echocardiography (ase) guidelines) due to mitral valve prolapse or flail * intermediate or high surgical risk for mitral valve repair exclusion criteria: * history of rheumatic heart disease * history of prior endocarditis * history of prior repair or replacement of the mitral valve, or annuloplasty * severely calcified mitral leaflet or has evidence of calcification in the grasping area of the leaflets that would prevent leaflet anchor positioning and deployment * complex mechanism of mr (leaflet perforation, severe leaflet calcifications, commissural extension, commissural prolapse, multiple flail or prolapsing segments, cleft) present on required imaging
transcranial magnetic stimulation in substance use disorder patients

Conditions: Substance Use Disorders

Summary: to determine the effect of substance use disorder on cortical excitability using transcranial magnetic stimulation (tms) , it's a scientific study

the numbers for substance use disorders are large, and we need to pay attention to them. data from the 2018 national survey on drug use and health suggest that, over the preceding year, 20.3 million people age 12 or older had substance use disorders, and 14.8 million of these cases were attributed to alcohol. when considering other substances, the report estimated that 4.4 million individuals had a marijuana use disorder and that 2 million people suffered from an opiate use disorder. it is well known that stress is associated with an increase in the use of alcohol and other substances, and this is particularly relevant today in relation to the chronic uncertainty and distress associated with the covid-19 pandemic along with the traumatic effects of racism and social injustice,trans-cranial magnetic stimulation (tms) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull). since its introduction in the mid-1980s is used to evaluate the cortico-spinal tract, cortical motor areas,, map motor and cognitive functions, study neural networks, and modulate brain function with a potential therapeutic aim, on one hand, the development of specific stimulation protocols, such as the cortical silent period (csp) and paired-pulse paradigms, as well as the emerging concept that motor cortical output is affected by non-primary motor areas, including the ventral and dorsal premotor cortex, supplementary motor area, and cingulate cortex, has allowed the use of tms to explore inhibitory and excitatory interactions within motor cortical regions in several neuropsychiatric disorders. different tms protocols can be used to study different components of cortical excitability and provide insight in to the regulation of different neurotransmitter systems.

Eligibility criteria:
inclusion criteria: 1. age:above18yearsold 2. males only 3. patients fulfilling diagnostic criteria of substance use disorder according to dsm-5 exclusion criteria: * 1. patients with other comorbid psychatric disorders. 2-patients with medical disease. 3.patients wirh epilepsy or family history of epilepsy. 4-cardiac pacemaker 5-metal implants in head as participant will be applied to magnetic field of the tms 6-age yonnger than 18
blood-bile ratio tacrolimus after liver transplantation

Conditions: Liver Transplant; Complications; Immunosuppression; Transplant Failure; Transplant; Complication, Rejection

Summary: tacrolimus is the most widely used immunosuppressive drug in the prevention of rejection after solid organ transplantation. pharmacokinetic studies in healthy volunteers and in transplanted patients have shown that this molecule is rapidly absorbed after oral administration (maximum plasma concentration after 1-2 hours), is found in the circulation bound mainly to erythrocytes and, after being metabolized by cyp3a4, is eliminated through the bile. the importance of the tacrolimus blood dosage is now widely recognized for detecting the immunosuppressive capacity reached in the individual patient or the eventual overdose of the drug. in the use of tacrolimus after liver transplantation, however, it is interesting to note that the biochemical pathway for metabolism and excretion of the drug is present in the transplanted organ, the main object of immunological and functional surveillance. the excretory capacity of tacrolimus by the liver through the bile, therefore, could be a useful tool for recognizing the early liver failure from a functional point of view, before the onset of hepatoecrosis.

prospective monocentric randomized study comparing two parallel groups: liver transplanted patients with early (10 pod) organ rejection (experimental arm); liver transplanted patients without early (10 pod) organ rejection (control arm) primary objective: evaluation of a correlation between the reduction of tacrolimus biliary excretion and the early liver failure primary endpoint: increase of tacrolimus blood-bile ratio measured before the onset of laboratory hepatonecrosis secondary objective: analysis of the cause of any drug-related toxicity secondary endpoint: correlation study between drug dosage and biliary excretion level in case of blood overdose or clinical evidence of pharmacological toxicity

Eligibility criteria:
inclusion criteria: * age ≥18 years * history of recent liver transplant (less than 10 days) * placement of kehr tube in the biliary tract during liver transplant * immunosuppressive therapy with tacrolimus * functioning of kehr tube exclusion criteria: * age - age ≥18 years * history of liver transplant for more than 10 days * liver transplant without positioning of kehr tube * immunosuppressive therapy with a drug different from tacrolimus * no functioning of kehr tube18 years * history of liver transplant for more than 10 days * liver transplant without positioning of kehr tube * immunosuppressive therapy with a drug different from tacrolimus * no functioning of kehr tube

Keywords: liver transplant; immunosuppression; transplant rejection;
immune response to bivalent and tetravalent human papillomavirus vaccine in hiv infected adults

Conditions: HIV; Human Papillomavirus

Summary: the purpose of this study is to analyze and compare the immunogenicity of bivalent and tetravalent vaccines against human papillomavirus in hiv-infected adult persons.


Eligibility criteria:
inclusion criteria: * hiv positive subjects. * age above 18 at the time of the first vaccination. * written informed consent obtained from the subject. * subjects whom the investigator believes can and will comply with the requirements of the protocol. * if currently on antiretroviral therapy (art), subjects must be compliant to triple therapy (highly active art) and have undetectable viral load for a period of six months prior to study entry. * female subjects of non-childbearing potential may be enrolled in the study. * female subjects of childbearing potential may be enrolled in the study, if the subject has a negative pregnancy test at screening and on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period. exclusion criteria: * previous vaccination against hpv, or planned administration of any hpv vaccine other than that foreseen by the study protocol during the study period (day 0 to month 12). * pregnant or breastfeeding female. * previous enrollment in the study. * subjects whom the investigator believes cannot and/or will not comply with the requirements of the protocol (i.e. because of abuse of drugs or alcohol, dementia or given medical, psychiatric, social or work related conditions). * chronic administration of immunosuppressive drugs * cancer or autoimmune disease * previous allergic reaction to vaccination * known allergy towards on or more components of either of the test drugs.
benefit of laparoscopic adhesiolysis in patients with chronische abdominal pain

Conditions: Chronic Pain; Adhesions

Summary: laparoscopic adhesiolysis as a therapy for chronic pain is still controversial and long term effects are not known. the objective was to to evaluate long term effects of laparoscopic adhesiolysis for treating chronic abdominal pain. therefore one hundred patients with abdominal pain attributed to adhesions were randomized to laparoscopic adhesiolysis or a placebo group with laparoscopy alone. pain relief was assessed after 3, 6 and 12 months and 12-year follow-up.

this multi-center randomized controlled trial, included patients with chronic abdominal pain likely to be caused by adhesions from previous abdominal surgery. chronic abdominal pain was defined as continues or intermittent abdominal pain of at least six months' duration. after excluding other pathology (see exclusion criteria) included patients underwent a diagnostic laparoscopy to confirm the adhesions and to exclude serious morbidity not visible with other diagnostics. if during laparoscopy adhesions were the only pathology present, patients were randomly assigned either to laparoscopic adhesiolysis or no treatment. for the randomization and surgical procedures the investigators refer to the original article. patients were unaware of their treatment assignment and the outcome assessment was blinded. abdominal pain and quality of life (qol) were assessed pre-operatively and at 3, 6 and 12 months of follow-using a visual analog scale (vas), verbal rating pain change score (vrcs) and the short form 36 (sf-36). after twelve months randomization was disclosed and placebo group patients with persisting abdominal pain could request laparoscopic adhesiolysis. after twelve year follow-up pain, qol, medical history and analgesic intake were analyzed to assess the long term effects of laparoscopic adhesiolysis.

Eligibility criteria:
inclusion criteria: * patients aged 18 years and above with chronic abdominal pain that was likely to be caused by adhesions due to previous abdominal surgery were recruited. before attributing abdominal pain to the existence of adhesions all patients had an extensional diagnostic work-up to exclude other pathology. exclusion criteria: * current treatment by psychologist or psychiatrist * use of laxatives, sedatives, morphine, antipsychotics, antidepressants, or drugs that stimulate the central nervous system * abnormal outcome of standardized non-invasive diagnostics: * biochemical investigation * lactose tolerance tests or h2 respiration test * feces analysis of worms and worm eggs * ultrasound or ct scan of the abdomen * radiographic studies of small and large bowel (or colonoscopy)

Keywords: chronic abdominal pain laparoscopic adhesiolysis placebo
pyrotinib in women with high-risk in early stage breast cancer

Conditions: HER2-positive Breast Cancer

Summary: extenet study explored neratinib prolong anti-her2 therapy after trastuzumab therapy found that it can improve disease-free survival in patients with lymph nodes positive; in addition, the subgroup of patients with residual tumors after neoadjuvant therapy was found to improve the survival. however, no conclusive conclusions were reached. however, since the study was carried out early so only trastuzumab treatment was used, it is urgent to carry out research that is more in line with current clinical practice and bring more benefits to patients. to explore whether pyrotinib can further reduce the risk of recurrence from previously diagnosed her2-positive breast cancer after treatment with trastuzumab and pertuzumab or t-dm1.


Eligibility criteria:
inclusion criteria: 1. subjects voluntarily participate in this study and sign the informed consent form； 2. female or male patients, aged ≥ 18 years, and ≤75 years; 3. ecog ps score: 0-1; 4. patients with her2+ early or locally advanced breast cancer confirmed by histopathology: her2-positive is defined by standard of 3+ by immunohistochemical staining (ihc), or 2+ by immunohistochemical staining (ihc) but positive by in situ hybridization (ish). 5. stage ii through iiic her-2 positive breast cancer with node positive disease after surgery. 6. been treated for early breast cancer with standard of care duration of trastuzumab combined with pertuzumab or t-dm1. 7. could have been treated neoadjuvantly but have not reached pathologic complete response. exclusion criteria: 1. metastatic disease (stage iv) or inflammatory breast cancer 2. previous or current history of malignant neoplasms, except for curatively treated:basal and squamous cell carcinoma of the skin,carcinoma in situ of the cervix. 3. clinically relevant cardiovascular disease:known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension ≥180/110); 4. a history of allergy to the drugs in this study； 5. unable or unwilling to swallow tablets 6. history of gastrointestinal disease with diarrhea as the major symptom.
does montelukast have an affect on the function of the artery in patients with heart disease

Conditions: Coronary Artery Disease; Acute Coronary Syndrome

Summary: to evaluate the effect of the drug montelukast on the brachial artery's function. by giving a drug like montelukast, which blocks the effects of inflammation in the lungs arteries and controls asthma, we hope to see positive effects in other arteries such as in the heart.

to measure the benefit of cysteinyl leukotriene blockade in favourably altering the pathophysiology of coronary artery disease. we hypothesize that patients admitted to hospital with acute coronary syndromes will have markedly abnormal endothelial function as measured by peripheral vasomotor responses to forearm ischemia. patients with myocardial infarction and unstable angina have markedly increased renal excretion of the cysteinyl leukotriene metabolite lte4 as observed in patients with asthma. observations that coronary vessel tone is negatively affected by leukotrienes c4,d4 and e4 which influences the atherosclerotic process in these arteries. studies that isolated the epicardial coronary arteries and challenged the vessels with an ltc4 and ltd4 concentration showed that coronary arterial myocytes were found to produce cysteinyl leukotrienes which lead to responsive vasoconstriction. the continued stimulus of vasoconstriction over time leads to endothelial dysfunction and disruption of the endothelium integrity which then leads to stressors that encourage a disease state and atherosclerosis.in this study we will specifically assess peripheral endothelial function by measuring brachial artery diameter changes and pat responses to temporary forearm ischemia in patients that have had an acute coronary event before and after receiving montelukast. as well we will measure leukotriene assays both in blood and urine .

Eligibility criteria:
inclusion criteria: * male or female age 18-80 years, diagnosis of acute coronary syndrome with one increased troponin assay,chest pain or chest pain syndrome, stable on initial medical therapy, painfree x 6 hours prior to enrollment exclusion criteria: * stemi, q-wave mi, \< 18years, women of childbearing potential, new lbbb, recurrent chest pain since hospitalization, iv nitroglycerine drip, hemodynamically unstable, history of asthma, history of liver disease or abnormal liver enzymes

Keywords: atherosclerosis inflammation leukotriene blockade endothelial function
use of the hattler respiratory assist catheter in severe respiratory failure

Conditions: Emphysema; Acute Respiratory Distress Syndrome; Chronic Obstructive Pulmonary Disease; Asthma; Respiratory Insufficiency

Summary: a new artificial lung device has been developed that potentially provides added support to mechanical ventilation for severely damaged lungs. the hattler respiratory assist catheter is designed to provide gas exchange (deliver oxygen and remove carbon dioxide) for a period of up to 7 days, providing more time for the lungs to improve. extrapolating from large animal data, the hypothesis is that the hattler catheter will be capable of providing 30% to 40% of the basal requirements of carbon dioxide exchange in a manner that is dependable and reproducible.

the hattler catheter respiratory assist device consists of a catheter and a drive console. the catheter consists of a bundle of polypropylene hollow fibers (approximately 1000) in 30cm or 35cm length surrounding a helium filled balloon. the balloon is similar to an intra-aortic balloon, however, it is pulsed at 300 beats per minute, while iabp typically operate at 120 bpm. the hollow fibers are similar to fibers utilized in external oxygenators for cardio-pulmonary bypass. no device exists on the market in which fibers surround a balloon, and no device exists on the market in which the hollow fiber bundle is designed to be inserted into the venous system, i.e., the vena cava. external oxygenators are designed to be used in an extracorporeal circulatory loop. the hattler catheter drive console provides the power to drive the helium filled balloon while removing excess oxygen and carbon dioxide from the venous system via the catheter.

Eligibility criteria:
inclusion criteria: * both sexes, 18 years and older * have a terminally ill disease process * on maximum ventilator support * intubated and unconscious * swan ganz in place * hypoxic * unsuitable for organ donation exclusion criteria: * circulatory shock (\< 80 mmhg) and unresponsive to drug therapy and volume replacement * pregnancy * morbid obesity \> 182 kg * weight \< 41 kg * history of bleeding disorders with contraindication to heparin * have a disease process with a contraindication to heparin * known internal jugular or femoral vein complications or abnormalities * known inferior vena cava (ivc) filter in place

Keywords: balloon fiber respiratory oxygenator heart failure ards copd
the clinical feature of ulcer base over time after prophylactic argon plasma coagulation in colonic emr

Conditions: Gastrointestinal Hemorrhage

Summary: the prophylactic apc right after colonic emr doesn't mean the complete coagulation of visible vessel because of injection material. the aim of this study was to evaluate the clinical feature of the visible vessels in ulcer base over time after prophylactic apc in colonic emr.

the prophylactic argon plasma coagulation (apc) of non-bleeding visible vessels seems not to have an additional advantage in the prevention of delayed post polypectomy bleeding in recently studies. however, immediate apc after endoscopic mucosal resection (emr) may not mean the complete coagulation of exposed vessels because of injection material. the aim of this study was to evaluate the clinical feature of the exposed vessels in ulcer base over time after prophylactic apc in colonic emr. methods: this study was designed as a prospective study. investigators excluded diminutive polyp, large polyp (\> 2cm), long stalk pedunculated polyp, and clear ulcer base after emr. between august 2013 and may 2014, patients who were enrolled underwent prophylactic apc for non-bleeding visible vessels after colonic endoscopic mucosal resection. after checking the complete coagulation of visible vessels, the numbers of visible vessel group were counted by lap of time such as 1, 3, 5, and 7 min in ulcer base.

Eligibility criteria:
inclusion criteria: * underwent prophylactic apc for non-bleeding visible vessels after colonic endoscopic mucosal resection. exclusion criteria: * diminutive polyp, large polyp (\> 2cm), long stalk pedunculated polyp, and clear ulcer base after emr.
effect of massage on hamstring muscle soreness

Conditions: Musculoskeletal Disorders

Summary: delayed onset muscular soreness peaks in 24-48 hours after unaccustomed strenuous physical exercise. therapists often provide manual massage with the hands to acutely relief the soreness. alternatives to manual hand massage can be useful for therapists. here the investigators examine the acute effect of a "massage roller" on doms in the hamstring muscles


Eligibility criteria:
inclusion criteria: * working age adults exclusion criteria: * blood pressure above 160/100 * disease of the cervical spine